AMLX
Amylyx Pharmaceuticals, Inc. NASDAQ Listed Jan 7, 2022$15.67
+2.75%
vs $15.25
Mkt Cap $1.5B
52w Low $5.02
79.8% of range
52w High $18.36
50d MA $15.18
200d MA $14.06
P/E (TTM)
—
EV/EBITDA
—
P/B
4.8x
Debt/Equity
0.0x
ROE
-47.4%
P/FCF
-12.0x
RSI (14)
59.90
ATR (14)
$0.92
Beta
-0.21
50d MA
$15.18
200d MA
$14.06
Avg Volume
1.3M
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
43 Thorndike Street · Cambridge, MA 02141 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 16.06 | -0.5% | -5.4% | -3.1% | +1.0% | -3.0% | +1.0% | — |
| Mar 3, 2026 | AMC | -0.31 | -0.30 | +3.2% | 14.11 | -0.3% | +6.7% | -6.3% | -1.8% | +3.3% | +4.7% | — |
| Nov 6, 2025 | AMC | -0.43 | -0.37 | +14.0% | 12.46 | +0.8% | -1.2% | -1.1% | +4.1% | -2.8% | +0.7% | — |
| Aug 7, 2025 | AMC | -0.44 | -0.46 | -4.5% | 7.84 | -0.3% | -2.6% | +2.4% | +4.9% | +1.2% | +1.3% | — |
| May 8, 2025 | AMC | -0.45 | -0.42 | +6.7% | 4.58 | -1.5% | +0.7% | -0.2% | -2.4% | -3.1% | +3.9% | — |
| Mar 4, 2025 | AMC | -0.49 | -0.55 | -12.2% | 3.01 | +0.0% | +11.6% | +7.4% | +7.2% | -9.8% | +6.9% | — |
| Nov 7, 2024 | AMC | -0.47 | -0.53 | -12.8% | 6.54 | +4.0% | +2.4% | +4.9% | -11.2% | -9.0% | -11.6% | — |
| Aug 8, 2024 | AMC | -0.38 | -0.73 | -92.1% | 1.80 | +1.1% | +5.6% | +4.2% | +0.5% | +7.0% | +1.4% | — |
| May 9, 2024 | AMC | 0.24 | -0.46 | -291.7% | 1.89 | -0.5% | -6.9% | +3.4% | +2.7% | -2.7% | +0.5% | — |
| Feb 22, 2024 | AMC | 0.23 | 0.07 | -69.6% | 18.54 | +1.0% | -4.8% | -0.5% | +8.2% | +3.0% | -3.7% | — |
| Nov 9, 2023 | AMC | 0.44 | 0.30 | -31.8% | 12.26 | +2.4% | +1.8% | +3.7% | -3.2% | +4.5% | -7.3% | — |
| Aug 10, 2023 | AMC | 0.10 | 0.31 | +210.0% | 21.17 | -0.8% | +2.0% | -2.9% | +0.1% | -4.7% | +1.0% | — |
| May 11, 2023 | AMC | -0.24 | 0.02 | +108.3% | 28.82 | +5.8% | -4.0% | +1.7% | -3.4% | +2.2% | -3.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | Mizuho | Maintains | Outperform → Outperform | — | $16.88 | $17.05 | +1.0% | -3.4% | -4.4% | +2.6% | +0.1% | +2.8% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.66 | $13.94 | +2.0% | +1.2% | -2.6% | +0.6% | -5.8% | +8.9% |
| Mar 19 | Guggenheim | Maintains | Buy → Buy | — | $13.79 | $13.98 | +1.4% | +1.9% | -1.7% | -2.0% | +1.0% | +1.2% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.11 | $14.07 | -0.3% | +6.7% | -6.3% | -1.8% | +3.3% | +4.7% |
| Feb 20 | BofA Securities | Maintains | Buy → Buy | — | $14.02 | $14.45 | +3.1% | -0.1% | -0.8% | +5.8% | -2.3% | +6.2% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.22 | $14.86 | +4.5% | +4.7% | -3.6% | -2.0% | +0.4% | +0.1% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.46 | $12.56 | +0.8% | -1.2% | -1.1% | +4.1% | -2.8% | +0.7% |
| Oct 17 | Citigroup | Maintains | Buy → Buy | — | $15.17 | $15.17 | +0.0% | -1.5% | +2.8% | -0.5% | -3.1% | -3.4% |
| Oct 16 | Baird | Maintains | Outperform → Outperform | — | $15.79 | $15.93 | +0.9% | -3.9% | -1.5% | +2.8% | -0.5% | -3.1% |
| Oct 3 | BofA Securities | Maintains | Buy → Buy | — | $13.29 | $13.56 | +2.0% | +1.0% | -5.4% | +6.3% | -0.1% | +7.3% |
| Sep 16 | Goldman Sachs | Maintains | Buy → Buy | — | $11.85 | $11.98 | +1.1% | +0.9% | +6.8% | +3.8% | +0.5% | +0.0% |
| Sep 15 | Guggenheim | Maintains | Buy → Buy | — | $11.65 | $12.05 | +3.4% | +1.7% | +0.9% | +6.8% | +3.8% | +0.5% |
| Aug 28 | BofA Securities | Maintains | Buy → Buy | — | $9.45 | $9.41 | -0.4% | -0.3% | -0.4% | +6.4% | -1.4% | +1.1% |
| May 14 | Mizuho | Maintains | Outperform → Outperform | — | $4.49 | $4.60 | +2.4% | -3.1% | +3.9% | +7.1% | +10.7% | +3.0% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.58 | $4.51 | -1.5% | +0.7% | -0.2% | -2.4% | -3.1% | +3.9% |
| May 7 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $4.65 | $5.10 | +9.7% | +4.7% | -6.0% | +0.7% | -0.2% | -2.4% |
| Apr 7 | Mizuho | Upgrade | Neutral → Outperform | — | $3.43 | $3.46 | +0.9% | +0.9% | -4.3% | +5.4% | +0.0% | +4.6% |
| Mar 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.01 | $3.01 | +0.0% | +11.6% | +7.4% | +7.2% | -9.8% | +6.9% |
| Dec 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.26 | $5.26 | +0.0% | -5.5% | +3.4% | -5.1% | -7.6% | -3.1% |
| Nov 18 | Baird | Upgrade | Neutral → Outperform | — | $4.76 | $5.23 | +9.9% | +11.3% | -1.5% | +0.2% | -0.8% | +1.5% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.54 | $6.80 | +4.0% | +2.4% | +4.9% | -11.2% | -9.0% | -11.6% |
| Oct 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.92 | $4.07 | +3.8% | +21.9% | -2.5% | -2.8% | +9.5% | -1.2% |
| Jul 12 | Goldman Sachs | Maintains | Neutral → Neutral | — | $2.28 | $2.32 | +1.8% | -5.3% | +0.0% | +9.3% | -10.2% | -5.7% |
| Jul 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.65 | $1.69 | +2.4% | +25.5% | +10.1% | -5.3% | +0.0% | +9.3% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.78 | $1.80 | +1.1% | +2.8% | +1.1% | -1.1% | +5.5% | -1.6% |
| May 14 | Mizuho | Maintains | Neutral → Neutral | — | $1.82 | $1.83 | +0.5% | +2.7% | -2.7% | +0.5% | +0.0% | +0.5% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.89 | $1.88 | -0.5% | -6.9% | +3.4% | +2.7% | -2.7% | +0.5% |
| Apr 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.46 | $2.45 | -0.4% | -6.9% | -8.3% | -1.4% | -2.9% | -0.5% |
| Apr 11 | Baird | Maintains | Neutral → Neutral | — | $2.46 | $2.45 | -0.4% | -6.9% | -8.3% | -1.4% | -2.9% | -0.5% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.62 | $2.65 | +1.1% | +2.7% | -0.7% | -7.9% | -6.9% | -8.3% |
| Mar 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.80 | $3.67 | -3.4% | -9.5% | +0.0% | -7.8% | +2.2% | -11.7% |
| Mar 11 | Goldman Sachs | Downgrade | Buy → Neutral | — | $3.36 | $3.33 | -0.9% | +13.1% | -9.5% | +0.0% | -7.8% | +2.2% |
| Mar 11 | Baird | Downgrade | Outperform → Neutral | — | $3.36 | $3.33 | -0.9% | +13.1% | -9.5% | +0.0% | -7.8% | +2.2% |
| Mar 11 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $3.36 | $3.33 | -0.9% | +13.1% | -9.5% | +0.0% | -7.8% | +2.2% |
| Mar 11 | Deutsche Bank | Maintains | Buy → Buy | — | $3.36 | $3.33 | -0.9% | +13.1% | -9.5% | +0.0% | -7.8% | +2.2% |
| Mar 8 | Evercore ISI | Downgrade | Outperform → In Line | — | $18.97 | $2.99 | -84.2% | -82.3% | +13.1% | -9.5% | +0.0% | -7.8% |
| Mar 8 | Mizuho | Maintains | Buy → Buy | — | $18.97 | $2.99 | -84.2% | -82.3% | +13.1% | -9.5% | +0.0% | -7.8% |
| Dec 21 | Mizuho | Maintains | Buy → Buy | — | $13.81 | $14.02 | +1.5% | +1.0% | +3.9% | -1.8% | +2.1% | +1.4% |
| Nov 10 | Goldman Sachs | Maintains | Buy → Buy | — | $12.26 | $12.56 | +2.4% | +1.8% | +3.7% | -3.2% | +4.5% | -7.3% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.26 | $12.56 | +2.4% | +1.8% | +3.7% | -3.2% | +4.5% | -7.3% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.17 | $21.01 | -0.8% | +2.0% | -2.9% | +0.1% | -4.7% | +1.0% |
| Jul 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.83 | $22.88 | +0.2% | -2.5% | +1.3% | +4.0% | -0.3% | -2.5% |
| Jul 24 | Goldman Sachs | Upgrade | Neutral → Buy | — | $22.55 | $24.16 | +7.1% | +1.6% | -1.8% | +1.5% | -2.5% | +1.3% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.04 | $24.27 | +1.0% | +2.7% | -1.0% | +3.0% | +0.4% | +1.1% |
| May 15 | Mizuho | Maintains | Buy → Buy | — | $27.67 | $28.13 | +1.7% | +1.7% | -3.4% | +2.2% | -3.4% | -0.6% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.82 | $30.50 | +5.8% | -4.0% | +1.7% | -3.4% | +2.2% | -3.4% |
| Mar 31 | Mizuho | Maintains | Buy → Buy | — | $27.71 | $28.50 | +2.9% | +5.9% | -2.5% | +0.1% | -2.9% | +4.5% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.17 | $37.19 | +19.3% | +9.4% | -1.5% | -4.5% | -5.6% | +4.9% |
| Mar 14 | Citigroup | Maintains | Buy → Buy | — | $31.17 | $37.19 | +19.3% | +9.4% | -1.5% | -4.5% | -5.6% | +4.9% |
| Mar 14 | Goldman Sachs | Maintains | Neutral → Neutral | — | $31.17 | $37.19 | +19.3% | +9.4% | -1.5% | -4.5% | -5.6% | +4.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 21, 2026 | Firestone Karen | — | Buy | 3,800 | $13.51 | $51K | 66,900 | +2.85% | -5.54% |
8-K · 2.02
!! High
Amylyx Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
Amylyx Pharmaceuticals disclosed quarterly earnings results via 8-K filing, with detailed financial performance metrics available in the attached press release exhibit for investor review.
May 7
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Amylyx Pharmaceuticals disclosed its strategic focus on endocrine and neurodegenerative disease therapies, signaling management's commitment to high-risk, high-reward drug development that could drive significant long-term value if successful.
Mar 24
8-K
Amylyx Pharmaceuticals, Inc. -- 8-K Filing
Amylyx Pharmaceuticals advanced its avexitide program for post-bariatric hypoglycemia and progressed its pipeline during 2025, demonstrating operational momentum for the clinical-stage biotech company.
Mar 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 16,630,541 | $231M | Added | Mar 2026 |
| 2 | Janus Henderson Group Plc | 4,986,073 | $69M | New | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 4,141,575 | $58M | New | Mar 2026 |
| 4 | Morgan Stanley | 4,719,648 | $57M | Added | Dec 2025 |
| 5 | Franklin Resources Inc | 2,261,569 | $31M | Added | Mar 2026 |
| 6 | Jones Hill Capital Lp | 1,598,794 | $22M | New | Mar 2026 |
| 7 | Bank Of America Corp /de/ | 1,330,689 | $18M | Added | Mar 2026 |
| 8 | Adar1 Capital Management, Llc | 1,000,604 | $14M | New | Mar 2026 |
| 9 | Barclays Plc | 971,854 | $14M | Added | Mar 2026 |
| 10 | Vanguard Portfolio Management Llc | 944,781 | $13M | New | Mar 2026 |
| 11 | Boxer Capital Management, Llc | 900,000 | $12M | Reduced | Sep 2025 |
| 12 | Connor, Clark & Lunn Investment Management Ltd. | 1,004,021 | $12M | Reduced | Dec 2025 |
| 13 | Woodline Partners Lp | 845,800 | $12M | — | Mar 2026 |
| 14 | Northern Trust Corp | 779,908 | $11M | Reduced | Mar 2026 |
| 15 | Qube Research & Technologies Ltd | 702,236 | $10M | Added | Mar 2026 |
| 16 | Stempoint Capital Lp | 669,685 | $9M | New | Mar 2026 |
| 17 | Jupiter Asset Management Ltd | 592,654 | $8M | Added | Mar 2026 |
| 18 | Silverarc Capital Management, Llc | 506,242 | $6M | Reduced | Dec 2025 |
| 19 | Citadel Advisors Llc | 411,532 | $6M | Added | Mar 2026 |
| 20 | Ubs Group Ag | 324,319 | $5M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.48B
Enterprise Value
$1.17B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.12x
P/B
4.85x
P/S
—
P/FCF
-12.00x
EV/EBITDA
—
Shares Out
94.6M
Financials (TTM)
Revenue
$0
Net Income
-$150.1M
EBITDA
-$147.7M
Free Cash Flow
-$123.5M
Op Cash Flow
-$123.3M
EPS Basic
$-1.53
EPS Diluted
$-1.48
EPS Forward
$-1.35
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$332.6M
Total Liab.
$27.4M
Total Equity
$305.3M
Cash
$317.0M
LT Debt
$4.7M
Book Value/Sh
$3.23
Debt/Equity
0.02x
Current Ratio
14.27
Quick Ratio
14.27
Returns & Growth
ROE
-47.4%
ROA
-43.5%
ROIC
-49.3%
Rev Growth YoY
-100.0%
EPS Growth YoY
+65.5%
Price Returns
2W
+3.4%
1M
-10.3%
3M
-5.4%
6M
-4.2%
12M
+178.6%
Technicals
52W High
$18.36
52W Low
$5.02
50d MA
$15.18
200d MA
$14.06
RSI (14)
59.90
ATR (14)
$0.92
Beta
-0.21
Avg Volume
1.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
4
Ex-Div Date
Mar 28, 2018
Analyst Price Targets
Consensus
$24.50
High
$28.00
Low
$21.00
Median
$24.50
Data updated apr 24, 2026 5:49pm
· Source: financialmodelingprep.com